JP2019535787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535787A5 JP2019535787A5 JP2019528502A JP2019528502A JP2019535787A5 JP 2019535787 A5 JP2019535787 A5 JP 2019535787A5 JP 2019528502 A JP2019528502 A JP 2019528502A JP 2019528502 A JP2019528502 A JP 2019528502A JP 2019535787 A5 JP2019535787 A5 JP 2019535787A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- disease
- compound according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- -1 haloalkyl hydroxy Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426629P | 2016-11-28 | 2016-11-28 | |
| US62/426,629 | 2016-11-28 | ||
| PCT/US2017/063232 WO2018098413A1 (en) | 2016-11-28 | 2017-11-27 | Pyrimidine carboxamides as gsk-3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535787A JP2019535787A (ja) | 2019-12-12 |
| JP2019535787A5 true JP2019535787A5 (https=) | 2020-11-12 |
| JP6977037B2 JP6977037B2 (ja) | 2021-12-08 |
Family
ID=60570273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528502A Active JP6977037B2 (ja) | 2016-11-28 | 2017-11-27 | Ｇｓｋ−３阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11053258B2 (https=) |
| EP (1) | EP3544968B1 (https=) |
| JP (1) | JP6977037B2 (https=) |
| KR (1) | KR102455408B1 (https=) |
| CN (1) | CN110198934B (https=) |
| ES (1) | ES2850773T3 (https=) |
| WO (1) | WO2018098413A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110545817B (zh) * | 2016-11-28 | 2022-11-15 | 百时美施贵宝公司 | Gsk-3抑制剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100376241B1 (ko) | 1997-10-03 | 2003-03-15 | 신닛폰 리카 가부시키가이샤 | 디아세탈 조성물, 그의 제법, 그 조성물을 포함하는 폴리올레핀용 기핵제, 폴리올레핀 수지 조성물 및 성형체 |
| JP2003096246A (ja) | 2001-09-27 | 2003-04-03 | New Japan Chem Co Ltd | 粒状ポリオレフィン樹脂用添加剤組成物の製造方法 |
| MX2008000461A (es) * | 2005-07-12 | 2008-03-10 | Abbott Gmbh & Co Kg | Compuestos de piridazina como inhibidores de la glucogeno sintasa cinasa 3. |
| JP5241834B2 (ja) * | 2007-07-19 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
| JP2013530199A (ja) * | 2010-07-06 | 2013-07-25 | ノバルティス アーゲー | キナーゼ阻害剤として有用な環状エーテル化合物 |
| CN102382359B (zh) | 2010-08-31 | 2013-08-14 | 中国石油化工股份有限公司 | 一种超细微有机磷酸盐成核剂的制备方法 |
| CN105849098A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | Gsk-3抑制剂 |
| CN105849097A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | 取代的吡啶衍生物用作gsk-3抑制剂 |
| CN110545817B (zh) * | 2016-11-28 | 2022-11-15 | 百时美施贵宝公司 | Gsk-3抑制剂 |
| EP3559103B1 (en) | 2016-12-21 | 2024-02-21 | Milliken & Company | Additive composition and methods for using the same |
-
2017
- 2017-11-27 ES ES17808729T patent/ES2850773T3/es active Active
- 2017-11-27 CN CN201780084339.6A patent/CN110198934B/zh active Active
- 2017-11-27 JP JP2019528502A patent/JP6977037B2/ja active Active
- 2017-11-27 EP EP17808729.2A patent/EP3544968B1/en active Active
- 2017-11-27 US US16/463,603 patent/US11053258B2/en active Active
- 2017-11-27 KR KR1020197018283A patent/KR102455408B1/ko active Active
- 2017-11-27 WO PCT/US2017/063232 patent/WO2018098413A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| JP2019038829A5 (https=) | ||
| JP2015512951A5 (https=) | ||
| JP2020502092A5 (https=) | ||
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| JP2016528301A5 (https=) | ||
| JP2015508092A5 (https=) | ||
| JP2019532079A5 (https=) | ||
| JP2020517607A5 (https=) | ||
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| JP2017514910A5 (https=) | ||
| TW200745135A (en) | Therapeutic agents | |
| JP2015500223A5 (https=) | ||
| JP2016522254A5 (https=) | ||
| EP4257190A3 (en) | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders | |
| IL282562A (en) | Composition and use for the treatment of parkinson's disease and related disorders | |
| JP2005534661A5 (https=) | ||
| RU2017112989A (ru) | Соединения и способы | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| JP2016537432A5 (https=) | ||
| TW200635589A (en) | Therapeutic agents | |
| JP2015534990A5 (https=) |